Volume 9, Issue 2 (6-2021)                   Jorjani Biomed J 2021, 9(2): 27-35 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

moshref javadi M, Abdolahad M, Soleimani N. Assessing the Effect of Freund Adjuvant on the 4T1 Breast Cancer Mice Model. Jorjani Biomed J. 2021; 9 (2) :27-35
URL: http://goums.ac.ir/jorjanijournal/article-1-817-en.html
1- Department of Microbiology and Microbial Biotechnology, Shahid Beheshti University, Tehran, Iran
2- Nano Electronic Center of Excellence, Nano Bio Electronic Devices Lab, School of Electrical and Computer Engineering, University of Tehran, Tehran, Iran
3- Department of Microbiology and Microbial Biotechnology, Shahid Beheshti University, Tehran, Iran , N_soleimani@sbu.ac.ir
Abstract:   (144 Views)
Background and Objective: Cancer immunotherapy combined with other common treatments can be an effective way to overcome cancerous cells. The purpose of this study was to investigate the effect of Freund Adjuvant on breast cancer in the BALB/c model of mice.
Material and Methods: Twenty female inbred 6–7-week-old- BALB/c mice were randomly divided into two groups of Test and Control, each containing 10 mice. Breast cancer was induced by injecting106 4T1 cells into the right flank region of mice. After the tumors were palpable; animals were immunized three times by intraperitoneal (IP) injection of Freund adjuvant in the test group and phosphate buffered saline (PBS) in the control group at same condition. During the study; tumor growth, body weight, and survival percentages in mice were measured by using the caliper method, and mortalities were recorded. Results were tabulated using Excel, and Graphpad Prism Version 8. Data were analyzed using One-Way ANOVA and T-test and the significance level for statistical tests was considered p≤0.05.
Results: The results showed that tumor mice given Freund Adjuvant had a significant reduction in tumor size compared to the control group (P=0.01) and no significant weight difference was observed between the two groups (P=0.4). Furthermore, Kaplan Meier showed that the survival of the mice in the Freund Adjuvant group was significantly increased compared to the control group (P=0.009).
Conclusion: This study showed that Freund Adjuvant may play an important role in improving the function of the immune system for cancer immunotherapy.
Immunotheray is stimulating bodys own immune system to work strongly or smartly to attack on cancer cells. Freund Adjuvant can be effective in immunotherapy for cancer by stimulating immune cells such as dendritic cells and T-cells and increasing the secretion of IFN-γ and other cytokines.
Type of Article: Original article | Subject: Basic Medical Sciences
Received: 2021/03/23 | Accepted: 2021/06/7 | Published: 2021/06/20

1. Houssami N, Hunter K. The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. npj Breast Cancer. 2017; 3:12. [DOI]
2. Al-Mahmood¬ S, Sapiezynski J, Garbuzenko O.B, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Delivery and Translational Research. 2018; 8(5):1483-1507. [DOI]
3. Bertucci F, Ng C.K.Y, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019; 569(7757):560-564. [DOI]
4. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019; 321(3):288-300. [DOI]
5. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. [DOI]
6. Corrales L, Matson V, Flood B, et al. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017; 27(1):96-108. [DOI]
7. Shihab I, Khalil B.A, Elemam N.M, et al. Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. Cancers. 2020; 12(8): 2226. [DOI]
8. Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy. Nature. 2019; 574(7776):45-56. [DOI]
9. Huang H, Zhou J, Chen H, et al. The immunomodulatory effects of endocrine therapy in breast cancer. J Exp Clin Cancer Res. 2021; 40(1):19. [DOI]
10. Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. The Journal of clinical investigation. 2016; 126(3):799-808. [DOI]
11. Bueno J. Bioprospecting and their Role in the Innovation of Vaccine Adjuvants: Mega Diversity as a Source of Competitiveness. J Microb Biochem Technol. 2017; 9(2):e130. [DOI]
12. Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER, et al. Adjuvant and carrier proteindependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Scientific reports. 2017; 7(1):40312. [DOI]
13. Apostólico JdS, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: classification, modus operandi, and licensing. Journal of immunology research. 2016; 2016(6):1-16. [DOI]
14. Bonam SR, Partidos CD, Halmuthur SKM, Muller S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends in pharmacological sciences. 2017; 38(9):771-93. [DOI]
15. Wang Z-B, Xu J. Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery. Vaccines. 2020; 8(1):128. [DOI]
16. Bastola R, Noh G, Keum T, et al. Vaccine adjuvants: smart components to boost the immune system. Archives of Pharmacal Research. 2017; 40(11):1238-1248. [DOI]
17. Hajam I.A, Dar P.A, Won G, et al. Bacterial ghosts as adjuvants: mechanisms and potential. Vet Res. 2017; 48(1): 37. [DOI]
18. Hawksworth D. Advancing Freund's and AddaVax Adjuvant Regimens Using CpG Oligodeoxynucleotides. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2018; 37(5):195-199. [DOI]
19. Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Frontiers in Oncology. 2018; 8:227. [DOI]
20. Tom JK, Albin TJ, Manna S, et al. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends in Biotechnology. 2019; 37(4):373-388. [DOI]
21. Shi S, Zhu H, Xia X, et al. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine. 2019; 37(24):3167-3178. [DOI]
22. Dewangan H.K, Singh S, Mishra R, Dubey R.K. A Review On Application Of Nanoadjuvant As Delivery System. International Journal of Applied Pharmaceutics. 2020; 12(4): 24-33. [DOI]
23. Nguyen A.T, Shiao S.L, McArthur H.L, et al. Advances in Combining Radiation and Immunotherapy in Breast Cancer. Clinical Breast Cancer. 2021; 21(2):143-152. [DOI]
24. Fahrer AM. A proposal for a simple and inexpensive therapeutic cancer vaccine, Immunology and Cell Biology. 2012; 90(3):310-3. [DOI]
25. Gottwein J.M, Blanchard T.G, Targoni O.S, et al. Protective Anti‐Helicobacter Immunity Is Induced with Aluminum Hydroxide or Complete Freund's Adjuvant by Systemic Immunization. The Journal of Infectious Diseases. 2001; 184(3):308-14. [DOI]
26. Ikeda H, Old L.J, Schreiber R.D. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002; 13(2):95-109. [DOI]
27. Ebbinghaus C, Ronca R, Kaspar M, et al. Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy, International Journal of Cancer. 2005; 116(2):304-313. [DOI]
28. García-Tuñón I, Ricote M, Ruiz A, et al. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer. 2007; 7:158. [DOI]
29. Pollack KE, Meneveau MO, Melssen MM, et al. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. Journal for Immuno Therapy of Cancer. 2020; 8(1):e000544. [DOI]
30. Slingluff CL, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009; 15(22):7036-44. [DOI]
31. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005; 175(9):6169-76. [DOI]
32. Kenter GG, Welters MJP, Valentijn ARPM, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009; 361:1838-47. [DOI]
33. Melssen M.M, Petroni G.R, Chianese-Bullock K.A, et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. J. immunotherapy cancer. 2019; 7(1):163. [DOI]
34. Marzo A.L, Kinnear B.F, Lake R.A, et al. Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. Journal of Immunology. 2000; 165(11):6047-6055. [DOI]
35. Assudani D.P, Horton R.B.V, Mathieu M.G, McArdle S.E.B, Rees R.C. The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother. 2007; 56(1):70-80. [DOI]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2021 CC BY-NC 4.0 | Jorjani Biomedicine Journal

Designed & Developed by : Yektaweb